Navigation Links
OrbusNeich Granted Expanded U.S. Patent of Genous™ Endothelial Progenitor Cell Capture Technology
Date:1/4/2011

FT. LAUDERDALE, Fla., Jan. 4, 2011 /PRNewswire/ -- OrbusNeich today announced that the United States Patent and Trademark Office (USPTO) has granted an additional patent expanding protection of the company's Genous endothelial progenitor cell (EPC) capture technology.

The patent (U.S. Pat. No. US 7,803,183) covers a coating on an implantable medical device that has one or more layers of a matrix.  Incorporated into the matrix are antibodies or antibody fragments that allow for capture in vivo of circulating EPCs.

"This patent further expands OrbusNeich's unique intellectual property portfolio of the Genous technology," said Robert Cottone, vice president of intellectual property and technologies at OrbusNeich. "We are continuing to develop our pro-healing technology for our next generation stent platform, which combines both luminal cell capture with abluminal drug elution and is currently in clinical trial evaluation."

About Genous  

Genous is OrbusNeich's patented EPC capture technology that promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents. The technology consists of an antibody surface coating that attracts EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.

The Genous Stent, which  has been commercially available in more than 60 countries since 2005, has been proven as a safe, effective alternative to drug-eluting stents and is supported by data from more than 5,000 patients in company-sponsored clinical studies. There is a growing body of evidence from multiple clinical studies that the Genous Stent is effective for patients who are non-responsive to or cannot tolerate long-term dual antiplatelet therapy.

About OrbusNeich

OrbusNeich is a global company that designs, develops, manufactures and markets innov
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. OrbusNeichs Genous™ Stent Shows Favorable Outcomes for Treatment of Coronary Artery Bifurcation Lesions Compared to Bare Metal Stents
2. Randomized Clinical Trial of OrbusNeichs Genous™ Bio-engineered R stent™ in China Completes Patient Enrollment
3. Data from Multiple Clinical Trials of OrbusNeichs Genous™ Bio-engineered R Stent™ Demonstrate Safety and Effectiveness Across Challenging Patient Subsets as Presented at TCT 2010
4. Patient Enrollment Completed in First Randomized Clinical Study of OrbusNeichs Combo™ Bio-engineered Sirolimus Eluting Stent
5. OrbusNeichs Genous™ Bio-engineered R stent™ Shows Favorable Safety Profile and Clinical Outcomes in Combination with Paclitaxel-Coated Balloon for De Novo Coronary Artery Disease
6. 100 Percent Coverage of Struts and Complete Neointimal Coverage of OrbusNeichs Genous™ Bio-engineered R stent™ Demonstrated 26 Days Post-Implantation in STEMI Patient
7. Data Show OrbusNeichs Genous™ Bio-engineered R stent™ is Safe and Effective in Combination with Drug-Eluting Balloon
8. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients
9. Data Presented at ACC/i2 Summit Demonstrate Impressive Long Term Clinical Outcomes in Real World Patients Treated with OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
10. OrbusNeich Announces First Patient Enrolled in Randomized Clinical Trial of Genous(TM) Bio-engineered R stent(TM) in China
11. Clinical Data Presented at Asia PCR/Sing LIVE Demonstrate Benefits of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) in Challenging Patient Subsets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... South Africa , May 6, ... kills more people than HIV/AIDS, malaria and tuberculosis combined[1]. Approximately ... percent can be cured with the right treatment[3]. Together with ... are working to build up their radiation therapy infrastructures and ... cancer patients worldwide would benefit from radiation therapy[4] during the ...
(Date:5/6/2015)... May 05, 2015 Research and Markets ... of the "Chromatography (Instruments and Reagents) Global ... their offering. Chromatography is an analytical ... component of a complex mixture by differential movement ... the scientists have considered chromatography as an esoteric ...
(Date:5/6/2015)... DUBLIN , May 06, 2015 Research ... announced the addition of the "Global Insulin ... offering. Highly advanced technology like ultrasound ... of modern insulin patches. Depending upon the type ... be out of reach of several patients. In ...
Breaking Medicine Technology:Elekta to bring cancer treatment to millions in Africa 2Elekta to bring cancer treatment to millions in Africa 3Elekta to bring cancer treatment to millions in Africa 4Global Chromatography (Instruments and Reagents) Market 2015 - Forecasts to 2019 2Global Insulin Patch Market Opportunity Analysis 2015 2
... 2011 Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, ... upcoming investor conferences in Paris.  Dr. Fernandes will present at ... CET, May 24, at the Hilton Arc de Triomphe.  Dr. ... at 3:00 p.m. CET, May 24, at the Paris Marriott ...
... 2011 Anaphore Inc. today announced that Michael ... joined Anaphore,s senior management team. Dr. ... and development partnership with Mitsubishi Tanabe Pharma Corporation, ... shaping Anaphore,s corporate strategy. Mr. Logan will work ...
Cached Medicine Technology:Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris 2Anaphore Appoints Michael F. Haller, Ph.D., Senior Vice President of Strategic Partnerships and H Casey Logan Senior Vice President of Business Development 2Anaphore Appoints Michael F. Haller, Ph.D., Senior Vice President of Strategic Partnerships and H Casey Logan Senior Vice President of Business Development 3
(Date:5/6/2015)... MA (PRWEB) May 06, 2015 ... for healthcare professionals and students, announced today that in ... 94% confirmed that use of the clinical decision support ... by the end of 2014, UpToDate users in more ... clinical topics per month, on average. In Germany alone, ...
(Date:5/6/2015)... Anitoa Systems, (“Anitoa”), a Palo Alto startup ... China, has successfully demonstrated a handheld real time quantitative-polymerase-chain-reaction ... Anitoa’s handheld qPCR is shown to be capable of ... hepatitis B, C, and E. Coli. This qPCR system ... and over 9 orders of magnitude dynamic range. ...
(Date:5/6/2015)... In March, Dr. Rami K. Batniji ... Masterclass. As Europe’s most exclusive rhinoplasty conference, the attendees ... Dr. Batniji was hand chosen to speak by the President ... Dr. Pietro Palma. , The Milano Masterclass is ... hosts a diverse, multi-national faculty; each considered a rhinoplasty expert ...
(Date:5/6/2015)... Locally owned, Greek olive oil producer and ... week as having one the best Extra Virgin Olive Oils ... Peloponnese region of Greece and known as Laconiko , ... of Medium Olive Oil, which is defined by the competition ... over 700 producer applicants from 25 different countries applying, Laconiko ...
(Date:5/6/2015)... The Alliance for Regenerative Medicine ... and advanced therapies community, today announced the release ... in-depth look at sector trends and metrics from ... report is available online here and ... available here . , Using information provided ...
Breaking Medicine News(10 mins):Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 2Health News:Current, Evidence-Based Knowledge for Physicians: UpToDate supports quick and accurate decision support for diagnosis and treatment 3Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 2Health News:Anitoa Systems Demonstrates Compact qPCR using Ultra Low-Light CMOS Bio-Optical Sensor 3Health News:California Surgeon Speaks at International Rhinoplasty Conference 2Health News:Greek Extra Virgin Olive Oil, Laconiko Wins Gold at the NYIOOC and Is Featured in Olive Oil Times as One of Greece's Best EVOO's for 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 2Health News:The Alliance for Regenerative Medicine Releases Quarterly Data Report, Highlighting Key Sector Trends and Metrics in Q1 2015 3
... labels to help cut heart disease, according to researchers from ... their arguments in this week's British Medical Journal, say that ... number one killer, estimated to be responsible for almost 50 ... cardiovascular disease is reported to cost the EU economy an ...
... because a staff nurse has refused to send an ambulance to ... had an agonizing pain in her lower abdomen. Hence she called ... could not have an ambulance and had to wait for another ... the GP arrived he just gave her some painkillers. ...
... 35-year-old woman in Madhya Pradesh survived carrying a dead foetus ... Friday at the government hospital at Khargone, 348 km from ... removed from her womb. ,Renubai conceived two years ... the seventh month of her pregnancy, her family members thought ...
... it has received the tentative new drug approval ... anti-HIV treatment. // ,The fixed drug ... Abacavir 300mg Tablets, the company informed the Bombay ... is cost-effective and reduces the threat of resistance ...
... of a bird flu vaccine against the deadly H5N1 variety ... unvaccinated monkeys, by researchers at two universities.// ,According ... University, the results are expected to be known within about ... shed light on numerous aspects of the strain's infection mechanism ...
... Act, celebrating its third anniversary, has reduced secondhand smoke ... a study conducted by RTI International. ,According to ... of Health’s Tobacco Control Program, exposure to secondhand smoke ... in the year following the implementation of the law. ...
Cached Medicine News:Health News:Scientists Push for Labeling of all Fats to Avoid Heart Disease 2Health News:New York’s Secondhand Smoke Exposure Continues to Declin 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: